Biogen International GmbH v Pharmacor Pty Ltd

Link copied
Case Copied 70 min read

FEDERAL COURT OF AUSTRALIA

Biogen International GmbH v Pharmacor Pty Ltd [2021] FCA 1591

File number(s): VID 443 of 2021
Judgment of: ROFE J
Date of judgment: 16 December 2021
Catchwords:  PRACTICE AND PROCEDURE – patents – interlocutory injunction application – prima facie case – validity of patents – extension of patent term – balance of convenience – quantification of potential loss and damage – application refused
Legislation:

Competition and Consumer Act 2010 (Cth)

Federal Court of Australia Act 1976 (Cth)

Patents Act 1990 (Cth)

Patents Amendment Act 2001 (Cth)

Therapeutic Goods Act 1989 (Cth)

Explanatory Memorandum to the Intellectual Property Laws Amendment Bill 1998 (Cth)

Terrell on the Law of Patents 19th ed (2021)

Cases cited:

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd & Ors (No 2) (2012) 96 IPR 185

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) 304 ALR 1

Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57

Beecham Group Limited v Bristol Laboratories Pty Ltd (1968) 118 CLR 618

Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618

Boehringer Ingelheim International GmbH v Commissioner of Patents (No. 2) (2001) 52 IPR 529

Boehringer Ingelheim International v Commissioner of Patents [2000] FCA 1918

Bristol Myers Squibb v FH Faulding & Co Ltd (2000) 97 FCR 524

Commissioner of Patents v Abbvie Biotechnology Ltd (2017) 125 IPR 398

Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis) (No 5) (2020) 151 IPR 237

Décor Corporation Pty Ltd & Anor v Dart Industries (1988) 13 IPR 385

Garford Pty Ltd v Dywidag Systems International Pty Ltd & Anor (2015) 110 IPR 30

Generic Health Pty Ltd & Anor v Bayer Pharma Aktiengesellschaft & Anor (2018) 137 IPR 1

H Lundbeck A/S v Sandoz Pty Ltd (2018) 137 IPR 408

Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1498

Meat & Livestock Australia v Cargill, Inc (2018) 129 IPR 278

Merrell Dow Pharmaceuticals In & Ors v HN Norton & Co Ltd (1995) 33 IPR 1

Myers Taylor Pty Ltd v Vicarr Industries Ltd (1977) 137 CLR 228

Mylan Health Pty Ltd & Anor v Sun Pharma ANZ Pty Ltd & Anor [2020] FCAFC 116

Novartis Pharmaceuticals Australia Pty Ltd v Bayer Australia Ltd (2015) 111 IPR 1

Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 4) (2015) 113 IPR 191

Prejay Holdings Ltd v Commissioner of Patents (2003) 57 IPR 424

Ramset Fasteners (Aust) Pty Ltd v Advanced Building Systems Pty Ltd (1999) 44 IPR 481

SamsungElectronics Co. Limited v Apple Inc. [2011] FCAFC 156

Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (2019) 139 IPR 409

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (2018) 136 IPR 8

Division: General Division
Registry: Victoria
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 286
Date of hearing: 29 October 2021
Counsel for the Applicants: Mr N Murray SC
Counsel for the Applicants: Mr B Mee
Counsel for the Respondent: Mr J S Cooke
Counsel for the Respondent:
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Biogen International GmbH v Pharmacor Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] FCA 1591
Decision Date

CaseChat Overview and Summary

Biogen International GmbH sought an interlocutory injunction against Pharmacor Pty Ltd, seeking to restrain the latter from launching generic versions of Biogen's multiple sclerosis drug, Tecfidera, into the Australian market. The case was heard in the Federal Court of Australia. The primary legal issues before the Court were the strength of Biogen's prima facie case for patent infringement and whether the balance of convenience and justice warranted the grant of the interlocutory relief sought.

The Court was required to assess the strength of Biogen's patent infringement case against Pharmacor. This included determining whether the Pharmacor products fell within the scope of the asserted claims of the patent, and whether Pharmacor's anticipated cross-claim for revocation of the asserted claims for invalidity and the assertion that the extension of the term of the patent was invalidly granted, qualified the strength of the infringement case. The Court also had to consider the balance of convenience and justice in deciding whether to grant the interlocutory relief.

The Court found that while Biogen had established a prima facie case for patent infringement, the balance of convenience and justice did not lie in favour of granting the interim relief sought. The Court was satisfied that Pharmacor was unlikely to enter the market before 1 February 2022, and that Biogen's potential loss and damage was not sufficiently quantifiable to warrant the grant of the interlocutory injunction. The Court also found that Pharmacor's arguments regarding the validity of the patent and the extension of its term had merit and warranted further consideration.

The Court dismissed Biogen's interlocutory application, refused to grant the injunction, and ordered that the time for filing an application for leave to appeal from these orders be extended to 31 January 2022. Biogen was also ordered to pay Pharmacor's costs of the application.

Orders

Orders of the court

Upon the respondent undertaking to keep accounts:

1. The applicant’s interlocutory application be dismissed.

2. The time for filing an application for leave to appeal from these orders be extended to 31 January 2022.

3. The applicants pay the respondent’s costs of this application.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Biogen International GmbH has brought an application for interlocutory injunctive relief against Pharmacor Pty Ltd, seeking to prevent the latter from listing and supplying generic versions of Biogen's pharmaceutical product, DMF, on the Pharmaceutical Benefits Scheme (PBS) in Australia. Biogen claims that the Pharmacor products infringe certain claims of a patent owned by Biogen, referred to as the Patent. The dispute involves the validity of the Patent and whether the Pharmacor products infringe it. Biogen has been preparing the launch of its generic products since August 2021, initially planning for a December 1, 2021 launch. However, it was later informed that the PBS would not list the Pharmacor products before February 1, 2022. Biogen asserts that the Pharmacor products fall within the scope of several claims of the Patent, while Pharmacor admits infringement of certain claims but denies others. The case also involves other companies, such as Accelagen, which has been enjoined from listing its generic products on the PBS while the Patent remains in force.

The matter came before the court on an urgent application for interlocutory injunctive relief. Biogen sought an injunction to prevent Pharmacor from listing and supplying its generic products on the PBS, arguing that such action would infringe the Patent and cause irreparable harm. The court heard evidence from several witnesses, including experts in pharmacology, health economics, and forensic accounting, as well as legal counsel. The application was heard and determined by the court, which ultimately decided not to grant the relief sought by Biogen. The court's decision included an extension of time for Biogen to apply for leave to appeal and an order for Biogen to pay Pharmacor's costs of the application.

Decision

Reasons for decision

The hearing of the application for injunctive relief was brought on urgently as Biogen apprehended that the Pharmacor Products might be listed on the PBS on the next listing date, 1 December 2021. Subsequent to the hearing, the Court was advised by the parties that the PBS had advised Pharmacor that the Pharmacor Products would not be listed on the PBS before 1 February 2022. 1.2 Summary of conclusion For the reasons set out below I have concluded that the balance of convenience and justice does not lie in favour of the grant of the interim relief sought.1.3 The witnesses Biogen relies on evidence from five witnesses:(a)Kylie Michele Bromley is the managing director of Biogen Australia and has a PhD in pharmacology. She has worked in the pharmaceutical industry in Australia for over 20 years. Dr Bromley gives evidence as to the Patent, the market for MS treatment in Australia, Tecfidera, the Pharmacor Products, the background to the dispute and the effect on Biogen if the Pharmacor Products are launched. Biogen relies on two affidavits from Dr Bromley.(b)Peter James Davey is a health economist with extensive knowledge of, and experience in, the pharmaceutical sector, including with respect to reimbursement and pharmaceutical pricing issues. Mr Davey has worked in the pharmaceutical sector since 1991 and has extensive experience in preparing economic modelling in that sector. Mr Davey gives opinion evidence as to what he considers would be involved in assessing the loss to Biogen if an interlocutory injunction was not granted and it is ultimately determined that the Patent is valid and infringed. Biogen relies on three affidavits from Mr Davey.(c)Owain Rhys Stone is a Partner at KordaMentha. He is a forensic accountant with significant experience in the pharmaceutical and life sciences sector including in the quantification of economic loss and damage in the context of pharmaceutical injunction disputes. Mr Stone describes the financial analysis he would employ to assess Biogen’s loss if Pharmacor is not restrained and the court finds the Patent valid and infringed. Biogen relies on two affidavits from Mr Stone.(d)William Neil Charman is a Sir John Monash distinguished Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University where he was Dean from 2007 to 2019. Professor Charman has expertise in the field of oral drug delivery and the design and assessment of pharmaceutical formulations for oral administration to humans. He gives evidence as to the prior art relied on by Pharmacor and responds to the evidence of Pharmacor’s expert. Biogen relies on one affidavit from Professor Charman.(e)Rebekah Frances Gay is a partner at Herbert Smith Freehills, Biogen’s solicitors. Ms Gay’s affidavit annexes search results, a decision of the Australian patent office finding claims 13 to 17 of the Patent novel over a prior art application on re-examination, and correspondence and documents relating to United States proceedings concerning Biogen’s related US patent in a dispute with Pharmacor’s ultimate parent company. Biogen relies on one affidavit from Ms Gay.

Ratio Decidendi

Legal Principle Established

Since August 2021, Pharmacor has been preparing for the launch and commencement of the supply of Pharmacor Products from 1 December 2021. As noted above, the Pharmacor Products will not be listed until at least 1 February 2022.1.8 Other ARTG registrations of DMF Accelagen Pty Ltd (Accelagen) is another company with ARTG registration for generic versions of DMF products. Accelagen has four DMF ARTG registrations. On 9 June 2021, Biogen commenced proceedings in this court against Accelagen and MSN Laboratories Private Ltd, India (MSN). On 19 July 2021, the Court made orders by consent enjoining Accelagen and MSN from, amongst other things, seeking listing of the Accelagen DMF products on the PBS whilst the Patent remains in force. Accelagen is not restrained from further transferring its ARTG registrations to third parties. Pursuant to the orders made by Beach J, Accelagen must give Biogen notice, within five days of any transfer of the sponsorship of any of its ARTG registrations to a third party. As a result, at the time of the hearing, Pharmacor was the only generic pharmaceutical company likely to be able to enter the DMF market in Australia on 1 December 2021. Subsequent to the hearing the Court was advised that the earliest date that Pharmacor will be able to enter the market if not restrained is 1 February 2022. 1.9 The issues The dispute concerns the question of the strength of the patent infringement case that Biogen advances and whether the balance of convenience and justice warrants the grant of the interlocutory relief sought. In the amended statement of claim Biogen asserts that the Pharmacor products are pharmaceutical preparations within the scope of at least claims 13, 14, 16, 17, 81, 86, 95, 96, 97 101, 102 and 103 of the Patent. Pharmacor admits that the Pharmacor products fall within the scope of claims 13, 14, 16 (as dependent on 13 or 14), 95, 96, 97, 101(as dependent on claims 95, 96 or 97), 102 (as dependent on any of 95, 96, 97 and 101) and 103 (as dependent on any of claims 95, 96, 97, 101 or 102) of the Patent. Pharmacor denies that the Pharmacor products fall within claims 81 or 86 (both of which are omnibus claims) of the Patent. In light of Pharmacor’s admissions, Biogen does not ask the Court to find a prima facie case of infringement on claims 81 and 86. Pharmacor denies that the Pharmacor products fall within claim 17 which claims a product containing an amount of active ingredient corresponding to 10mg to 300mg of fumaric acid. In the context of the strength the prima facie case the remaining issue on the infringement case is whether claim 17 is infringed. Pharmacor submits that the strength of the infringement case is qualified by its foreshadowed cross-claim for revocation of the asserted claims for invalidity, and the assertion that the extension of term of the Patent was invalidly granted. For the purposes of the interlocutory application, Pharmacor confined its invalidity case at the hearing to a novelty attack to the asserted claims, on the basis of one prior art document: Australian patent application no. 21393/99 (the 593 Application).